Achieve Life Sciences Inc QUIT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
AchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates
Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
Trading Information
- Previous Close Price
- $6.40
- Day Range
- $6.29–6.54
- 52-Week Range
- $2.64–8.62
- Bid/Ask
- $6.45 / $6.47
- Shares Outstanding
- 110.03M
- Market Cap
- $662.69M
- Volume/Avg
- 328,493 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Achieve Life Sciences Inc is a late-stage specialty pharmaceutical company focused on the world-wide development and commercialization of cytisinicline as a treatment for nicotine dependence. Its New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two completed Phase 3 studies and an open-label long-term safety study. It has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
Valuation
Metric | QUIT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.89 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
QUIT
Financial Strength
Metric | QUIT |
|---|---|
Quick Ratio | 10.39 |
Current Ratio | 10.49 |
Interest Coverage | −108.15 |
Quick Ratio
QUIT
Profitability
Metric | QUIT |
|---|---|
Return on Assets (Normalized) | −92.09% |
Return on Equity (Normalized) | −208.03% |
Return on Invested Capital (Normalized) | −165.26% |
Return on Assets
QUIT
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%@KLl?^ | LOCK|Sv@! | $139B | |||
| Moderna Inc MRNA | LOCK|>>hh&f | LOCK|m^H | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Q>v?mf | LOCK|#xqPc | $95B | |||
| argenx SE ADR ARGX | LOCK|!S!^g&& | LOCK|rjG | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|qpY$?T< | LOCK|CfD | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|GDrWF<y | LOCK|Zn##> | $31B | |||
| Incyte Corp INCY | LOCK|BpY??PD | LOCK|H?$ | $25B | |||
| BioNTech SE ADR BNTX | LOCK|GZ#$&tw | LOCK|<g | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|#@WLql | LOCK|<H@vK | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&>&%>y | LOCK|#% | $16B |
United States